乳腺癌患者心房颤动的发生率、危险因素与死亡率:SEER-Medicare分析
乳腺癌后新发房颤1年发生率为3.3%(95%CI 3.0-3.5%),高于对照的1.8%(95%CI 1.6-2.0%);AJCC II/III/IV期较I期房颤风险增高,新发房颤与1年心血管死亡率升高相关。
要点
- 乳腺癌后1年新发房颤发生率为3.3%,前60天最高(0.6%/月)。
- AJCC II/III/IV期较I期房颤风险逐渐增高(aHR 1.51/2.63/4.21)。
- 乳腺癌后新发房颤与1年心血管死亡率升高相关(aHR 3.00)。
核心结论
- 乳腺癌诊断后房颤发生率显著高于匹配的无癌症对照。
- 乳腺癌分期越高,房颤风险越高。
- 新发房颤增加1年心血管死亡率,但不增加乳腺癌相关死亡率。
研究设计与样本
- 基于SEER-Medicare关联数据库的回顾性队列研究。
- 乳腺癌患者与无癌症的Medicare参保者1:1个体匹配,每对随访1年以识别房颤。
- 采用竞争风险生存统计计算累积发生率,调整Cox比例风险模型识别危险因素并评估死亡率。
主要发现
- 乳腺癌诊断后1年内新发房颤2993例(3.9%),1年发生率为3.3%(95%CI 3.0-3.5%),前60天发生率最高(0.6%/月)。
- 匹配的非癌症对照者新发房颤发生率为1.8%(95%CI 1.6-2.0%)。
- 除传统人口学和心血管危险因素外,AJCC II/III/IV期较I期与房颤发生强相关(aHR分别为1.51/2.63/4.21)。
- 乳腺癌诊断后新发房颤与1年心血管死亡率升高相关(aHR 3.00)。
临床怎么用
- 乳腺癌患者,尤其分期较晚者,应关注房颤筛查与监测。
- 乳腺癌诊断后新发房颤提示心血管死亡风险升高,鼓励心脏肿瘤学参与管理以改善心血管及总体预后。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: The national incidence, risk factors, and associated mortality of atrial fibrillation (AF) in breast cancer patients are unknown. METHODS AND RESULTS: Using the Surveillance, Epidemiology, and End Results-Medicare-linked database, we identified females, ≥66 years old, with a new primary diagnosis of breast cancer from 2007 through 2014. These patients were individually matched 1:1 to Medicare enrolees without cancer, and each pair was followed for 1 year to identify a primary outcome of AF. Cumulative incidence was calculated using competing risk survival statistics. Following this, identifying risk factors of AF among breast cancer patients was conducted using the adjusted Cox proportional hazards model. Finally, Kaplan-Meier methods and adjusted Cox proportional hazards modelling were performed to estimate mortality in breast cancer patients with incident and prevalent AF. This study included 85 423 breast cancer patients. Among these 9425 (11.0%) had AF diagnosis prior to the breast cancer diagnosis. New-onset AF was diagnosed in 2993 (3.9%) patients in a 1-year period after the breast cancer diagnosis [incidence 3.3%, 95% confidence interval (CI) 3.0-3.5%, at 1 year; higher rate in the first 60 days (0.6%/month)]. Comparatively, the incidence of new-onset AF in matched non-cancer controls was 1.8% (95% CI 1.6-2.0%). Apart from traditional demographic and cardiovascular risk factors, breast cancer stage was strongly associated with the development of AF [American Joint Committee on Cancer (AJCC) Stage II/III/IV vs. I: adjusted hazard ratio (aHR) 1.51/2.63/4.21, respectively]. New-onset AF after breast cancer diagnosis (aHR 3.00) is associated with increased 1-year cardiovascular mortality. CONCLUSION: AF incidence is significantly higher in women after a breast cancer diagnosis. Higher breast cancer stages at diagnos are significantly associated with a higher risk of AF. New-onset AF in the new breast cancer diagnosis setting increases 1-year cardiovascular mortality but not breast cancer-related mortality. KEY QUESTION: What are the incidence, prevalence, risk factors and mortality outcomes of atrial fibrillation (AF) in a multi-ethnic representative United States cohort of breast cancer patients? KEY FINDING: Annual incidence for AF is 3.9% with highest rate in the first 60 days after cancer diagnosis. Cancer stage and grade are the strongest risk factors for AF. New onset AF after breast cancer increases all-cause and cardiovascular mortality. TAKE HOME MESSAGE: AF incidence is higher in breast cancer patients and is associated with later stage and grade at diagnosis of breast cancer. Involving cardio-oncology in those who develop AF after cancer diagnosis should be encouraged to improve their cardiovascular and overall prognosis.
引用
- Guha A, Fradley MG, Dent SF, et al. Incidence, risk factors, and mortality of atrial fibrillation in breast cancer: a SEER-Medicare analysis. Eur Heart J. 2022. PMID: 34791123. doi:10.1093/eurheartj/ehab745
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。